The former managing director of Murray Goulburn will be hit with a $200,000 penalty for being knowingly concerned in false representations made by the dairy producer to farmers about the farmgate milk prices it would pay during the 2015-16 milk season.
Former Reserve Bank of Australia official Christian Boillot was sentenced Thursday to a two and a half years’ suspended jail term over his role in a conspiracy to bribe foreign officials to win banknote business.
Ramsay Health Care has defeated a challenge to its Nuramel trade mark for a brand of infant formula, with IP Australia saying while the mark was an exact anagram of Biofarma’s Munarel, it wasn’t deceptively similar.
ANZ treasurer Rick Moscati was at the centre of a flurry of phone calls and meetings with underwriters and other bank executives on the day the underwriters agreed to pick up a $791 million shortfall in a $2.5 billion capital raising, an agreement which has led to groundbreaking cases by two regulators, according to a new court document.
AMP’s advice executive Jack Regan, the witness who aired the firm’s fees-for-no-service dirty laundry at the Royal Commission, has retired, a day before five law firms compete to lead a class action over the scandal.
Former HWL Ebsworth special counsel Dr Gary Rumble’s insistence that he believed he had carte blanche to criticise one of the law firm’s clients is an “untenable stretch,” the Federal Court heard Wednesday.
Internet provider Activ8me is in hot water with the consumer regulator for a second time this year, facing court action over allegedly false and misleading claims about the cost, speed and data limits of its internet packages.
Medical device maker B. Braun Melsungen is appealing a ruling that invalidated its intravenous catheter patents and dismissed allegations of infringement against rival Becton Dickinson.
A judge applied the “wrong test” when he considered the reputation of a trade mark in an infringement case alleging the marks of rival meat processors were deceptively similar, a Full Federal Court has found.
Pharmaceutical giant Wyeth has accused Merck Sharp & Dohme of a “baseless” patent invalidity case, saying on the second day of trial over the world’s best selling vaccine that the development of its patented Prevnar 13 pneumococcal shot was anything but obvious, as its rival contends.